EGFR- and ALK-targeted treatment: present and future - memoinOncology
Kaplan-Meier analyses of survival in patients treated with alectinib... | Download Scientific Diagram
Supplemental Materials for Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial - The Lancet
Alectinib Yields Better Overall Survival Than Ceritinib in ALK-Positive Non–Small Cell Lung Cancer
Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study - Annals of Oncology
JALEX Phase III Trial of Alectinib versus Crizotinib
ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials - Journal of Thoracic Oncology
First-Line PFS - ALECENSA® (alectinib)
Expanding treatment options in NSCLC patients with rare mutations: ALK, ROS1, MET, BRAF - memoinOncology
Progression-free survival of patients with ALK-positive NSCLC | Download Scientific Diagram
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer - Lung Cancer
Alectinib for treatment of ALK-positive non-small-cell lung cancer | Future Oncology
Frontiers | Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients | Oncology
Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib | Journal of Comparative Effectiveness Research
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study -
YIR On Demand Lung Benjamin Levy, MD Assistant Professor - ppt download
Overall Survival Data: Primary & Exploratory 5-Year Landmark Analysis - ALECENSA® (alectinib)
Progression-free survival by IRC Shown is the Kaplan-Meier curve for... | Download Scientific Diagram
Potent treatment options in ALK– and MET-positive disease - memoinOncology
Roche - European Commission approves Roche's Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - Annals of Oncology
Cancers | Free Full-Text | Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer with or without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis | HTML
Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non–Small Cell Lung Cancer - Journal of Thoracic Oncology
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer | NEJM
First-Line PFS - ALECENSA® (alectinib)
Supplemental Materials for Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial - The Lancet Oncology
Alectinib & crizotinib improved survival outcomes of NSCLC | OTT
